Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Current & emerging biomarkers in multiple myeloma

Noemí Puig • 26 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, outlines current and emerging biomarkers used at diagnosis in multiple myeloma, highlighting the potential of circulating tumor plasma cells as a prognostic factor in both smoldering myeloma and multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Noemí Puig

Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma 2:17
Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
Noemí Puig • 18 Sep 2025
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA 3:49
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
Noemí Puig • 18 Sep 2025
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM 2:20
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
Noemí Puig • 7 Oct 2024
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice 1:49
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice
Noemí Puig • 7 Oct 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals